EXECUTIVE SUMMARY
Advanced lung cancer in 2024 is not the death sentence it was a decade ago pregnancy symptoms first week. Seven treatments now push survival curves past the two-year mark for subsets of patients. Yet none are cures, all carry toxicity, and access remains uneven. This review strips away the hype to show what each therapy actually delivers, who it helps, and who it harms.
GENUINE BENEFITS
TARGETED TKIS: PRECISION WITH PILL-BASED CONTROL
Third-generation EGFR inhibitors osimertinib and aumolertinib shrink tumors in 80 % of EGFR-mutant patients. Progression-free survival (PFS) stretches to 19–22 months. Patients swallow a daily pill at home, avoiding chemotherapy infusions. Side effects—rash, diarrhea, rare pneumonitis—are usually manageable with dose adjustments.
IMMUNE CHECKPOINT INHIBITORS: DURABLE RESPONSES FOR THE RIGHT BIOMARKER
Pembrolizumab and atezolizumab produce five-year survival rates of 25–30 % in PD-L1–high tumors (≥ 50 %). Responses can last years after stopping treatment. These drugs work best in non-squamous histology and never-smokers with high tumor mutational burden. Toxicity—colitis, pneumonitis, endocrinopathies—can be life-threatening but often reversible with steroids.
ANTIBODY-DRUG CONJUGATES: TARGETED CHEMO DELIVERY
Trop-2–directed datopotamab deruxtecan (Dato-DXd) and HER2-directed trastuzumab deruxtecan (T-DXd) deliver potent cytotoxic payloads directly to tumor cells. Objective response rates (ORR) reach 50–60 % in heavily pre-treated patients. The narrow therapeutic window means interstitial lung disease (ILD) occurs in 10–15 % of patients, sometimes fatal.
KRAS G12C INHIBITORS: FIRST EFFECTIVE TREATMENT FOR A COMMON MUTATION
Sotorasib and adagrasib achieve ORR of 40–45 % in KRAS G12C–mutant NSCLC. Median PFS is 6–7 months, a meaningful gain over docetaxel. Side effects—diarrhea, liver enzyme elevations, rare gastrointestinal perforation—are usually reversible with dose holds. Resistance emerges quickly, limiting long-term benefit.
BISPECIFIC ANTIBODIES: T-CELL ENGAGERS FOR SMALL-CELL LUNG CANCER
Tarlatamab, a DLL3-targeted bispecific T-cell engager, shows ORR of 40 % in relapsed small-cell lung cancer (SCLC). Median duration of response exceeds six months. Cytokine release syndrome (CRS) occurs in 50 % of patients, requiring inpatient monitoring for the first cycle. This is the first new SCLC drug in decades with a novel mechanism.
COMBINATION CHEMO-IMMUNOTHERAPY: FRONT-LINE STANDARD FOR NON-DRIVER MUTATIONS
Platinum doublet plus pembrolizumab extends median overall survival (OS) to 22 months in non-squamous NSCLC without actionable mutations. The regimen is now standard first-line therapy. Toxicity—fatigue, nausea, neutropenia—is cumulative and often limits quality of life. Patients with poor performance status (ECOG ≥ 2) rarely tolerate the full course.
LOCAL ABLATIVE THERAPIES: STEREOTACTIC RADIATION FOR OLIGOMETASTATIC DISEASE
Stereotactic body radiotherapy (SBRT) to 1–5 metastatic sites achieves local control rates of 80–90 %. When combined with systemic therapy, it can prolong PFS by 6–12 months. Toxicity—pneumonitis, esophagitis—is site-dependent but usually transient. Not all patients have oligometastatic disease, and insurance often denies coverage for more than three sites.
REAL DRAWBACKS OR LIMITATIONS
RESISTANCE IS INEVITABLE
Every targeted therapy eventually fails. EGFR T790M, KRAS G12C secondary mutations, and MET amplification drive resistance within 12–24 months. Liquid biopsies detect resistance early, but subsequent treatment options are limited. Patients cycle through drugs until no effective therapies remain.
TOXICITY IS UNDERESTIMATED
Immune-related adverse events (irAEs) from checkpoint inhibitors can mimic autoimmune diseases. Grade 3–4 pneumonitis occurs in 5 % of patients, with a 1 % fatality rate. Antibody-drug conjugates cause ILD in 10–15 % of patients, sometimes after a single dose. These toxicities are not always reversible and can permanently disable.
ACCESS IS NOT UNIVERSAL
Targeted therapies cost $15,000–$20,000 per month. Even with insurance, copays can exceed $1,000 monthly. Rural patients lack access to specialized centers for SBRT or bispecific antibody infusions. Clinical trial enrollment is often the only way to access cutting-edge treatments, but trials have strict eligibility criteria.
WHO IT’S GENUINELY RIGHT FOR
PATIENTS WITH ACTIONABLE DRIVER MUTATIONS
EGFR, ALK, ROS1, RET, NTRK, BRAF V600E, KRAS G12C, and MET exon 14 skipping mutations have FDA-approved targeted therapies. These